- Trials with a EudraCT protocol (28,960)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
28,960 result(s) found for: Informed Consent.
Displaying page 741 of 1,448.
| EudraCT Number: 2021-004137-36 | Sponsor Protocol Number: TIG-007 | Start Date*: 2022-02-16 | |||||||||||
| Sponsor Name:iTeos Belgium SA | |||||||||||||
| Full Title: Study of EOS884448 alone, and in combination with iberdomide with or without dexamethasone, in participants with relapsed or refractory multiple myeloma | |||||||||||||
| Medical condition: Relapsed or refractory multiple myeloma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) ES (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-006053-22 | Sponsor Protocol Number: NLX-112-DYS-101 | Start Date*: 2021-09-22 |
| Sponsor Name:Neurolixis SAS | ||
| Full Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 versus Placebo in Levodopa-induced Dyskinesia in Parkinson’s Disease | ||
| Medical condition: Parkinson´s disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2023-001028-40 | Sponsor Protocol Number: RIV-PN-201 | Start Date*: 2024-01-15 | |||||||||||
| Sponsor Name:United Therapeutics Corp | |||||||||||||
| Full Title: Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo-Controlled, Safety and Efficacy Study | |||||||||||||
| Medical condition: Persistant Pulmonary Hypertension of the Newborn (PPHN) | |||||||||||||
|
|||||||||||||
| Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-003722-41 | Sponsor Protocol Number: IOV–GB–1-2014-REGOMA | Start Date*: 2015-04-24 | |||||||||||
| Sponsor Name:Istituto Oncologico Veneto – IOV‐IRCCS | |||||||||||||
| Full Title: Regorafenib in relapsed glioblastoma. REGOMA study Randomized, controlled open‐label phase II clinical trial | |||||||||||||
| Medical condition: Glioblastoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-000647-27 | Sponsor Protocol Number: Ibu19 | Start Date*: 2019-12-18 | ||||||||||||||||
| Sponsor Name:Dicofarm S.p.A. | ||||||||||||||||||
| Full Title: Evaluation of efficacy and bioavailability of a new pediatric formulation based on ibuprofen lysinate vs ibuprofen in the management of pain in children | ||||||||||||||||||
| Medical condition: Pain on an inflammatory basis (otitis and otomastoiditis, adenite, cellulite, arthritis) and post-operative pain | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2018-002936-26 | Sponsor Protocol Number: 17-157 | Start Date*: 2019-11-28 |
| Sponsor Name:Heinrich-Heine-University Düsseldorf | ||
| Full Title: Efficacy and safety of Trifluridine/Tipiracil in combination with Irinotecan as a second line therapy in patients with Cholangiocarcinoma | ||
| Medical condition: Patients with advanced, non resectable or metastatic cholangio- and gallbladder carcinoma after failure to respond to a previous gemcitabine treatment. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-004689-93 | Sponsor Protocol Number: 207497 | Start Date*: 2019-04-29 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
| Full Title: A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lena... | |||||||||||||
| Medical condition: Relapsed / Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-002151-10 | Sponsor Protocol Number: NEUROPROTECTpost-CA | Start Date*: 2015-08-07 | |||||||||||
| Sponsor Name:UZ Leuven | |||||||||||||
| Full Title: Neuroprotective goal directed hemodynamic optimization in post-cardiac arrest patients: a randomized controlled trial (the NEUROPROTECT post-CA trial) | |||||||||||||
| Medical condition: post-cardiac arrest patients | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-001490-33 | Sponsor Protocol Number: UC-0110/1608 | Start Date*: 2016-10-25 | |||||||||||
| Sponsor Name:UNICANCER | |||||||||||||
| Full Title: Phase II randomized study comparing FOLFIRINOX + Panitumumab versus mFOLFOX6 + Panitumumab in metastatic colorectal cancer patients selected by RAS and B-RAF status from circulating DNA analysis. | |||||||||||||
| Medical condition: RAS and B-RAF wild-type metastatic colorectal cancer. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-004617-12 | Sponsor Protocol Number: INTEGRATE_IIb | Start Date*: 2023-07-04 | |||||||||||
| Sponsor Name:Australasian Gastro-Intestinal Trials Group (AGITG) | |||||||||||||
| Full Title: INTEGRATE IIb - A Randomised Phase III Open Label Study of regorafenib + nivolumab vs standard chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) | |||||||||||||
| Medical condition: refractory, advanced gastro-oesophageal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-001611-37 | Sponsor Protocol Number: T2F12017 | Start Date*: 2019-02-27 |
| Sponsor Name:Medical University Vienna, Gender Medicine Unit, Div. of Endocrinology, Dep of Medicine III | ||
| Full Title: A 52 week prospective randomized controlled study to investigate the effect of intramuscular testosterone undecanoate supplementation vs placebo on intrahepatic fat content in overweight/obese men ... | ||
| Medical condition: hypogonadism, T2DM, prediabetes, overweight, obesity | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male | |
| Trial protocol: AT (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-002640-82 | Sponsor Protocol Number: EANITIATE1 | Start Date*: 2018-11-20 | |||||||||||
| Sponsor Name:Nordsjællands Hospital | |||||||||||||
| Full Title: A randomized, controlled, multicentre trial regarding the safety and feasibility of treatment with empagliflozin compared with NPH insulin treatment in patients with newly onset diabetes following ... | |||||||||||||
| Medical condition: Diabetes Mellitus that is induced by the use of glucocorticoids | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-003221-22 | Sponsor Protocol Number: TAK-555-3010 | Start Date*: 2024-01-15 |
| Sponsor Name:Takeda Development Center Americas, Inc. | ||
| Full Title: Phase 3, Multicenter, Randomized Study With 2 Different Doses of Prucalopride Administered to Male and Female Pediatric Subjects Aged 6 Months to 17 Years With Functional Constipation, Consisting o... | ||
| Medical condition: Constipation | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2018-000708-40 | Sponsor Protocol Number: UC-0110/1719 | Start Date*: 2018-12-05 |
| Sponsor Name:UNICANCER | ||
| Full Title: Association of Radiochemotherapy and Immunotherapy for the treatment of unresectable Oesophageal caNcer: a comparative randomized phase II trial. | ||
| Medical condition: Localised unresectable adenocarcinoma or squamous cell carcinoma of the oesophagus without any prior chemotherapy, surgery, or radiotherapy | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2024-000165-25 | Sponsor Protocol Number: mRNA-1273-P306 | Start Date*: 2024-05-30 |
| Sponsor Name:ModernaTX, Inc. | ||
| Full Title: An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of mRNA Vaccines for SARS-CoV-2 Variants in Participants Aged 6 Months to <6 Years | ||
| Medical condition: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-002499-14 | Sponsor Protocol Number: PI2018_843_0051 | Start Date*: 2021-05-26 |
| Sponsor Name:CHU Amiens-Picardie | ||
| Full Title: RELYAGE (Relapse LYmphoma AGEd) : Assessment of survival and autonomy with Rituximab-Lenalidomide and Rituximab-Chemotherapy for elderly patients with relapsed diffuse large-B cell lymphoma : a ran... | ||
| Medical condition: diffuse large B cell lymphoma | ||
| Disease: | ||
| Population Age: Elderly | Gender: Male, Female | |
| Trial protocol: FR (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-006106-23 | Sponsor Protocol Number: 2020/3210 | Start Date*: 2021-07-21 | |||||||||||
| Sponsor Name:Gustave Roussy | |||||||||||||
| Full Title: Short-term Pre-OPerative Durvalumab (MEDI 4736) in early small triple negative breast cancer patients | |||||||||||||
| Medical condition: Untreated operable small triple negative breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-003153-39 | Sponsor Protocol Number: SDRFTT | Start Date*: 2021-12-01 | |||||||||||
| Sponsor Name:Bispebjerg Hospital, Department of Dermatology | |||||||||||||
| Full Title: Treatment of striae distensae with fractional radiofrequency and topical tretinoin: An intra-individual study with blinded outcome assessment | |||||||||||||
| Medical condition: Striae Distensae | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-000319-21 | Sponsor Protocol Number: ClonDO | Start Date*: 2021-12-20 |
| Sponsor Name:Charité – Universitätsmedizin Berlin | ||
| Full Title: Treating Nightmares in Posttraumatic Stress Disorder with the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibility Study (ClonDoTrial) | ||
| Medical condition: Posttraumatic Stress Disorder | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-002835-17 | Sponsor Protocol Number: 250774 | Start Date*: 2016-01-18 | ||||||||||||||||||||||||||
| Sponsor Name:Justus Liebig Universität Gießen | ||||||||||||||||||||||||||||
| Full Title: Investigation of the influence of PAH-specific medication on right ventricular function in patients with pulmonary arterial hypertension (PAH) under basal conditions | ||||||||||||||||||||||||||||
| Medical condition: Pulmonary arterial Hypertension (PAH) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.